Powder: -20°C for 3 years | In solvent: -80°C for 1 year
ODN 21595, a guanine-modified inhibitor targeting TLR7 and TLR9, effectively inhibits the release of IFN-α and IL-6 without exhibiting cytotoxicity. It also reduces the expression of CD86 and HLA-DR, showcasing potential for systemic lupus erythematosus (SLE) research [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry | |
50 mg | Inquiry | Inquiry |
Description | ODN 21595, a guanine-modified inhibitor targeting TLR7 and TLR9, effectively inhibits the release of IFN-α and IL-6 without exhibiting cytotoxicity. It also reduces the expression of CD86 and HLA-DR, showcasing potential for systemic lupus erythematosus (SLE) research [1]. |
Molecular Weight | N/A |
CAS No. | 1964506-28-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
ODN 21595 1964506-28-2 inhibitor inhibit